LQDA Loses 13.9% in a Month: Should Investors Avoid the Stock Now?

LQDA dropped 13.9% over the past month despite Yutrepia gaining traction with more than 5,000 patients on therapy as of July 2026. Analysts at Zacks Investment Research now recommend avoiding the stock, citing an unfavorable risk-reward profile driven by four key headwinds.

The company's heavy reliance on Yutrepia as its sole commercialized product concentrates revenue risk. Ongoing patent litigation with UTHR threatens market exclusivity, while competitive pressures in the pulmonary arterial hypertension space compound uncertainty. Rising research and development costs are squeezing margins as LQDA attempts to diversify its pipeline.

The negative analyst call follows significant underperformance despite clinical adoption milestones. Yutrepia's 5,000-patient milestone demonstrates demand, but the single-product model leaves little room for error as legal and competitive threats loom.